The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders

Dalin Li, Alexander Xu, Emebet Mengesha, Rebecca Elyanow, Rachel M. Gittelman, Heidi Chapman, John C. Prostko, Edwin C. Frias, James L. Stewart, Valeriya Pozdnyakova, Philip Debbas, Angela Mujukian, Arash A Horizon, Noah Merin, Sandy Joung, Gregory J. Botwin, Kimia Sobhani, Jane C. Figueiredo, Susan Cheng, Ian M. Kaplan, Dermot P.B. McGovern, Akil Merchant, Gil Y. Melmed, Jonathan Braun
doi: https://doi.org/10.1101/2021.12.08.21267444

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Back to top
Posted December 08, 2021.
Download PDF
Data/Code
Email
The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders
Dalin Li, Alexander Xu, Emebet Mengesha, Rebecca Elyanow, Rachel M. Gittelman, Heidi Chapman, John C. Prostko, Edwin C. Frias, James L. Stewart, Valeriya Pozdnyakova, Philip Debbas, Angela Mujukian, Arash A Horizon, Noah Merin, Sandy Joung, Gregory J. Botwin, Kimia Sobhani, Jane C. Figueiredo, Susan Cheng, Ian M. Kaplan, Dermot P.B. McGovern, Akil Merchant, Gil Y. Melmed, Jonathan Braun
medRxiv 2021.12.08.21267444; doi: https://doi.org/10.1101/2021.12.08.21267444
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area